STIFEL 2026 HEALTHCARE CONFERENCE - OUTSET MEDICAL INC

Financial Performance:

• Q3 revenue grew 14% year-over-year and 6% sequentially, with all revenue lines contributing to growth.
• Console revenue specifically surged 26% in Q3.
• Revenue is 70%+ recurring; consumables (treatments) account for ~50% of total revenue.
• EMR revenue (integration fees, maintenance, subscriptions) grew over 20% year-over-year.
• Gross margin is currently constrained by low-margin console sales but targets a 50% long-term goal via high-margin software and service expansion.
• No specific EPS, net income, or cash flow figures provided in this transcript excerpt.

Guidance and Future Outlook:

• Maintained 2026 revenue guidance at $125 million to $130 million despite Q3 beat, citing prudence and desire to set a strong foundation for 2027.
• Management aims for double-digit revenue growth in 2027 and beyond, projecting a ~17% growth rate in the second half of the year following the first half.
• Next-generation Tableau system is expected to roll out methodically in late Q4 or early 2027 to ensure operational readiness and patient safety.
• Long-term strategy focuses on margin expansion, profitability, and leveraging data/AI to drive efficiency.

Business Segments and Product Lines:

• Console Drivers: Growth fueled by three layers: "Refresh" (6-7 year lifecycle replacements, $150M+ opportunity), "Expansion" (deploying into new ICU or health system facilities), and "New Customer Acquisitions."
• Key Validation: Secured a major refresh agreement with HCA, the largest US health system, validating the insourcing value proposition.
• EMR Integration: Unique selling point as the only dialysis system fully integrated with Epic and Cerner; revenue model includes upfront fees and recurring maintenance.
• Home Dialysis: Currently accounts for a small portion of revenue (85% is acute/critical care); near-term focus remains on acute profitability, though home retention rates (90%+ at 1, 6, and 12 months) exceed industry averages.
• Sales Force Optimization: New commercial leadership (Derek) has refined territory sizing and compensation to prioritize "solution selling" and expansion within the existing installed base.

Market and Competitive Landscape:

• Policy Tailwinds: HHS launched a national plan to transform kidney care, explicitly encouraging home dialysis and new technology adoption, which aligns with Outset's mission.
• Cost Pressures: Tightening hospital budgets favor Outset's value proposition of >50% cost reduction through insourcing, making the story "evergreen" during fiscal tightening.
• Competition: Outset holds a distinct advantage with superior patient retention rates compared to earlier home dialysis entrants and unique EMR integration.
• Market Dynamics: Focus on the top 250 hospitals to maximize treatment volume and per-console revenue; total acute care TAM estimated at $2.2 billion.

Risks and Challenges:

• Capital Equipment Cycle: Sales cycles remain long (9-12 months), though conversion is typically full once a decision is made.
• Next-Gen Rollout: Risk of delaying software release to ensure safety; management committed to a slow, deliberate approach rather than rushing.
• Regulatory Environment: Upcoming FDA cybersecurity requirements for 2025 and potential changes in US administration policy (though management views kidney care as bipartisan).
• Budget Uncertainty: While hospital budget tightening is seen as a tailwind, general healthcare funding shifts (Medicare/Medicaid) remain a monitoring factor.

Management Commentary and Tone:

• Tone: Highly confident, optimistic, and strategic; management emphasizes "prudent conservatism" regarding guidance while highlighting strong execution.
• Strategic Shift: Explicit pivot from solely chasing new logos to aggressively monetizing the existing installed base via expansion and refresh cycles.
• Innovation: Future roadmap heavily weighted toward software, data analytics, and AI integration rather than significant hardware form-factor changes.
• Home Strategy: Near-term patience on home growth, prioritizing acute market penetration to achieve profitability first.

Analyst Questions and Answers:

• Q: Impact of HHS National Plan?
  • A: Viewed as a major positive catalyst; aligns with company mission to increase home dialysis and new tech adoption; potential policy urgency may accelerate before election outcomes.
• Q: Hospital budget tightening concerns?
  • A: Not a primary worry; cost-reduction value prop makes the solution more attractive as hospitals focus on the bottom line.
• Q: Drivers of Q3 growth?
  • A: Strong performance across refresh, expansion, and new customer segments, supported by high utilization rates and 20% growth in EMR revenue.
• Q: 2027 growth acceleration requirements?
  • A: Requires continued execution on all revenue streams, specifically engaging the 3,000+ consoles entering the refresh cycle and driving deeper expansion in existing facilities.
• Q: Next-gen Tableau pricing and timeline?
  • A: Expected to command higher prices and margins due to added software value; rollout delayed until late Q4/early 2027 to ensure "rule of no harm."
• Q: Path to 50% gross margin?
  • A: Targeted for years 3-5; depends on shifting mix toward high-margin software and service revenues, as console sales are intentionally low-margin.
• Q: Home dialysis growth catalysts?
  • A: Retention rates are the key driver; training time (2 weeks) now matches industry gold standard, allowing providers to expand patient census efficiently.

Other Key Points:

• Data Advantage: The system streams data for every treatment (3.5 million data points per treatment), enabling real-time utilization monitoring and future AI-driven insights.
• Cybersecurity: Outset claims to be the first to meet 2025 FDA cybersecurity requirements for the medical device industry.
• Strategic Prioritization: Management has refocused the sales organization to prioritize the "sediment layers" of the business (existing customers) over new acquisition alone.
• Acute vs. Home: Outset remains an acute care/critical care company by design for the near term, with home viewed as a long-term, high-growth opportunity contingent on retention success.